It is important that unnecessary or excessive radiation be avoided. The dosage levels for routine and macroradiography were measured (Fig 2) . It will be seen that the surface dose for macroradiography (58 mr) is approximately twice that for a standard chest X-ray taken with fast tungstate screens (27 mr), but because the area irradiated is smaller the integral (body) dose for macroradiography (110 gram-rontgens) is only two-thirds that for the standard chest X-ray (180 gram-rontgens). To further reduce the quantity of radiation the routine lateral chest X-ray was omitted for all patients having a macroradiograph except when, following examination of the routine chest film, a lateral film was considered essential. It is probable, therefore, that the average patient during this trial received a smaller body dose than he would otherwise have had.
On reviewing all the films taken during this period the following conclusions were reached:
(1) The examination (macroradiography) did not appear to be of value in those patients who had (a) gross lesions, (b) lesions which produce a cloudy or ground glass type of shadowing.
(2) The examination did appear to be of value in (a) assessing whether or not a fine 'infiltrate' was present, (b) assessing changes in such a lesion.
It has been found that the use of macroradiography of the lung requires a reappraisal of one's criteria for normality. In general, a portion of lung field on a standard chest X-ray is regarded as normal when the main vascular shadows are well defined and the background (summation) shadowing is within the accepted range, neither too much nor too little, for the type of chest and the area of lung being examined.
In macroradiographs of lung the background shadowing tends to be more clearly and sharply shown and any granularity or loss of definition in the main vascular shadows is more evident. Therefore the criteria for normality have to be modified towards an acceptance of a more prominent background shadowing.
[A demonstration of macroradiographs illustrating the points made was provided.] Acknowledgments: I am indebted to Dr D G James for permission to carry out this study on the patients attending his sarcoidosis clinic at the Royal Northern Hospital, London, and to Mr J M Wilkinson, Physicist to the Hospital, for the measurements of radiation dosage quoted. 
Extrathoracic Sarcoidosis
Sarcoidosis is chameleon-like in its modes of presentation (Table 1) for it is a multisystem disease in which intrathoracic manifestations are predominant, but in which other systems and organs are frequently involved. By the design of this symposium, our communication is limited to extrathoracic sarcoidosis but relating whenever relevant to corresponding intrathoracic disease. Clinical material: In a ten-year period, 1,080 patients attended a sarcoidosis clinic, principally at the Royal Northern Hospital. Our statistical analysis is limited to 537 patients with a secure diagnosis of sarcoidosis on both clinical and histological grounds ( Table 2 ). Evidence of one without the other is insufficient, for clinical or radiological manifestations alone present too wide a differential diagnosis; and, conversely, isolated histological evidence could be merely a nonspecific local sarcoid tissue reaction. In this series of 537 patients, there was intrathoracic involvement in 452 (84 %), ocular manifestations (Table 3) , it is rarely due to sarcoidosis. This is a fact which should be remembered particularly when granulomas are incidentally disclosed by the surgeon, gastroenterologist or endoscopist performing diagnostic biopsies. Bone cysts: They were radiologically evident in 19 of 537 patients (4%). They are most commonly seen in conjunction with chronic skin lesions, and it is indeed possible to generalize by saying that a dermatologist is much more likely to find them than a chest physician. It is a waste of time and money to do routine X-rays of hands and feet in the absence of chronic skin lesions; and in this context erythema nodosum is not accompanied by bone cysts. The presence or absence of bone cysts is predictable if it can be judged whether sarcoidosis is acute or chronic (Table 4 ). The type and fate of sarcoidosis belongs to one of two patterns, irrespective of the organ or system of involvement. Chronic sarcoidosis in one system reflects chronic fibrotic sarcoidosis elsewhere. Bone cysts reflect chronic persistent sarcoidosis in all systems.
Treatment
The only treatment which influences the clinical, radiological, histological, immunological and biochemical abnormalities is corticosteroid therapy. It may be given by mouth or locally to skin and eyes. Intralesional triamcinolone is most effective for disfiguring skin plaques alone or in 51 993 conjunction with oral corticosteroids or chloroquine. Oral corticosteroids may contribute several unpleasant side-effects, not the least being fluid retention and a cushingoid facies. These undesirable sequelb may be overcome by using a new potent oral corticosteroid, Sintisone, which does not seem to be fluid-retaining. When patients are converted from other steroids to Sintisone, they appear to lose fluid, the weight drops a little and mooning of the face lessens. Preliminary evidence would also suggest that it is less likely to cause a rise in intraocular pressure, and thereby less likely to contribute to secondary glaucoma.
The indications for corticosteroid treatment are:
(1) Ophthalmic involvement: For anterior uveitis topical corticosteroids may be sufficient, in the form of eye drops applied frequently during the day and ointment at night, perhaps reinforced by a local subconjunctival depot of cortisone. Oral corticosteroids are indicated if local treatment does not lead to a rapid response or if ophthalmoscopsy reveals posterior uveitis.
(2) An abnormal chest radiograph which does not show any spontaneous improvement in the course of six months. It may prevent the development of irreversible pulmonary fibrosis.
(3) Breathlessness: Corticosteroid treatment provides symptomatic relief but does not, of course, overcome irremediable pulmonary fibrosis and disturbed gas transfer. (4) Persistent hypercalciuria: Steroids will prevent excessive gastrointestinal absorption and excessive urinary excretion of calcium. Instead, calcium is diverted to a harmless ftcal excretion.
(5) Disfiguring skin lesions: When lupus pernio or other unsightly lesions distress patients, oral and local corticosteroids may correct the deformity. Unfortunately small doses of steroids must be continued indefinitely if the cosmetic improvement is to be maintained. (6) Neurological involvement: The more acute the disease, the more likely it is to respond to corticosteroid treatment. (7) Glandular involvement, particularly if there is disordered function, e.g. dry eyes due to lacrimal gland involvement, dry mouth due to salivary gland enlargement, and hypersplenism due to sarcoidosis of the spleen.
Summary
Sarcoidosis is a multisystem disease in which intrathoracic involvement is predominant, for it occurs in 84 % of cases, but there is also involvement of eyes in 27 %, erythema nodosum in 31 %, other skin lesions in 25%, splenomegaly (12%), neurosarcoidosis (7 %), parotid involvement (6 %), bone cysts (4%). The natural history of the disease is similar in all systems. Erythema nodosum is associated with transient hilar lymphadenopathy, whereas chronic skin lesions and bone cysts reflect persistent pulmonary fibrosis. The type and extent of extrathoracic sarcoidosis determine the prognosis of the intrathoracic disease. Bone cysts are the hallmark of chronicity of sarcoidosis. Corticosteroid treatment is indicated for: ophthalmic involvement; when a chest radiograph reveals pulmonary involvement for longer than six months; breathlessness; persistent hypercalciuria; disfiguring skin lesions; neurological and glandular involvement.
